Literature DB >> 7827239

Reduced risk of breast and endometrial cancer among women with hip fractures (Sweden).

I Persson1, H O Adami, J K McLaughlin, T Naessén, J F Fraumeni.   

Abstract

To test the hypothesis that osteoporosis, which results partly from long-term estrogen deficiency, is associated with a lowered risk of breast and endometrial cancer, a population-based cohort study was performed in Sweden. Some 18,000 women were followed through record-linkages after a first hip fracture, on average for almost six years, to ascertain the incidence of breast and endometrial cancer. Expected numbers were derived from the general population. Overall, 253 cases of breast cancer were observed cf 300 expected (standardized incidence ratio [SIR] = 0.84; 95 percent confidence interval [CI] = 0.74-0.95). Forty-eight cases of endometrial cancer were found cf 55 expected (SIR = 0.87, CI = 0.54-1.16). There was no clearcut pattern of breast cancer risk by age at diagnosis of hip fracture, follow-up time, or calendar period. Our results are consistent with the a priori hypothesis that long-term estrogen deficiency is associated with a reduced risk of developing breast cancer as well as endometrial cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7827239     DOI: 10.1007/bf01831380

Source DB:  PubMed          Journal:  Cancer Causes Control        ISSN: 0957-5243            Impact factor:   2.506


  33 in total

1.  Hip fractures in women with breast cancer.

Authors:  H O Adami; M Zack; U Kressner; I Persson; A Berglund; T Naessén; L Bergkvist
Journal:  Am J Epidemiol       Date:  1990-11       Impact factor: 4.897

2.  A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.

Authors:  K K Steinberg; S B Thacker; S J Smith; D F Stroup; M M Zack; W D Flanders; R L Berkelman
Journal:  JAMA       Date:  1991-04-17       Impact factor: 56.272

Review 3.  Epidemiology of breast cancer.

Authors:  J L Kelsey; M D Gammon
Journal:  Epidemiol Rev       Date:  1990       Impact factor: 6.222

Review 4.  The antiestrogenic effect of cigarette smoking in women.

Authors:  J A Baron; C La Vecchia; F Levi
Journal:  Am J Obstet Gynecol       Date:  1990-02       Impact factor: 8.661

5.  Epidemiology of vertebral fractures in women.

Authors:  L J Melton; S H Kan; M A Frye; H W Wahner; W M O'Fallon; B L Riggs
Journal:  Am J Epidemiol       Date:  1989-05       Impact factor: 4.897

6.  Perimenopausal risk of falling and incidence of distal forearm fracture.

Authors:  S J Winner; C A Morgan; J G Evans
Journal:  BMJ       Date:  1989-06-03

7.  Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females.

Authors:  C Christiansen; M S Christensen; P McNair; C Hagen; K E Stocklund; I Transbøl
Journal:  Eur J Clin Invest       Date:  1980-08       Impact factor: 4.686

8.  Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study.

Authors:  D P Kiel; D T Felson; J J Anderson; P W Wilson; M A Moskowitz
Journal:  N Engl J Med       Date:  1987-11-05       Impact factor: 91.245

9.  Health and social status in patients with hip fractures and controls.

Authors:  O Johnell; I Sernbo
Journal:  Age Ageing       Date:  1986-09       Impact factor: 10.668

Review 10.  Time trends in incidence rates of first hip fracture in the Uppsala Health Care Region, Sweden, 1965-1983.

Authors:  T Naessén; R Parker; I Persson; M Zack; H O Adami
Journal:  Am J Epidemiol       Date:  1989-08       Impact factor: 4.897

View more
  13 in total

Review 1.  The epidemiology of endometrial and ovarian cancer.

Authors:  Daniel W Cramer
Journal:  Hematol Oncol Clin North Am       Date:  2011-11-25       Impact factor: 3.722

2.  Breast cancer and bone mass in older women: is bone density prescreening for mammography useful?

Authors:  D Kritz-Silverstein; D L Schneider; J Sandwell
Journal:  Osteoporos Int       Date:  2006-05-13       Impact factor: 4.507

3.  Is there a reduced risk of breast cancer among women with hip fractures?

Authors:  O Ganry; J Peng; A Dubreuil
Journal:  Eur J Epidemiol       Date:  1999-04       Impact factor: 8.082

4.  Oral bisphosphonate use and risk of postmenopausal endometrial cancer.

Authors:  Polly A Newcomb; Michael N Passarelli; Amanda I Phipps; Garnet L Anderson; Jean Wactawski-Wende; Gloria Y F Ho; Mary Jo O'Sullivan; Rowan T Chlebowski
Journal:  J Clin Oncol       Date:  2015-02-23       Impact factor: 44.544

5.  Fracture risk in women with breast cancer: a population-based study.

Authors:  L Joseph Melton; Lynn C Hartmann; Sara J Achenbach; Elizabeth J Atkinson; Terry M Therneau; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2012-05       Impact factor: 6.741

6.  Bone fractures and incident epithelial ovarian cancer in a prospective cohort study.

Authors:  Kim N Danforth; Catherine Schairer; Arthur Schatzkin; James V Lacey
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

7.  Risk of endometrial cancer in relation to medical conditions and medication use.

Authors:  Joan Fortuny; Camelia Sima; Sharon Bayuga; Homer Wilcox; Katherine Pulick; Shameka Faulkner; Ann G Zauber; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-04-21       Impact factor: 4.254

8.  Bone mass density and risk of breast cancer and survival in older women.

Authors:  O Ganry; C Baudoin; P Fardellone; J Peng; N Raverdy
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

9.  HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice.

Authors:  Claire-Sophie Devignes; Yetki Aslan; Audrey Brenot; Audrey Devillers; Koen Schepers; Stéphanie Fabre; Jonathan Chou; Amy-Jo Casbon; Zena Werb; Sylvain Provot
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-16       Impact factor: 11.205

10.  Sex steroid hormones, bone mineral density, and risk of breast cancer.

Authors:  L H Kuller; J A Cauley; L Lucas; S Cummings; W S Browner
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.